Clinical Trials Logo

JS001 clinical trials

View clinical trials related to JS001.

Filter by:
  • None
  • Page 1

NCT ID: NCT04116918 Recruiting - NSCLC Stage IV Clinical Trials

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Start date: September 1, 2019
Phase:
Study type: Observational

This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.